Egyptian International Pharmaceutical Investments (CAI:PHAR) ROCE %: 26.44% (As of Mar. 2026)


CAI:PHAR Egyptian International Pharmaceutical Investments CAI:PHAR
69 GF Score
Price E£85.22
GF Value E£59.67
Valuation Significantly Overvalued
! 12 Warning Signs
View Full Analysis

What is Egyptian International Pharmaceutical Investments ROCE %?

Egyptian International Pharmaceutical Investments CAI:PHAR -3.71% 69 ROCE % is 26.44% as of Mar. 2026. GuruFocus rates CAI:PHAR with a GF Score™ of 69/100 and a GF Value™ of E£59.67 (Significantly Overvalued). The stock has 12 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Egyptian International Pharmaceutical Investments's annualized ROCE % for the quarter that ended in Mar. 2026 was 26.44%.

Egyptian International Pharmaceutical Investments  (CAI:PHAR) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Egyptian International Pharmaceutical Investments ROCE % Related Terms

Egyptian International Pharmaceutical Investments ROCE % Historical Data

* Premium members only.

The historical data trend for Egyptian International Pharmaceutical Investments's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Egyptian International Pharmaceutical Investments ROCE % Chart

Egyptian International Pharmaceutical Investments Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 22.31 22.96 26.02 26.14 29.56

Egyptian International Pharmaceutical Investments Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.78 32.81 39.16 27.68 26.44
CAI:PHAR
69GF Score
Egyptian International Pharmaceutical Investments CAI:PHAR
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Egyptian International Pharmaceutical Investments ROCE % Calculation

Egyptian International Pharmaceutical Investments's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=2458.914/( ( (9978.783 - 2830.735) + (15372.957 - 5886.708) )/ 2 )
=2458.914/( (7148.048+9486.249)/ 2 )
=2458.914/8317.1485
=29.56 %

Egyptian International Pharmaceutical Investments's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Sep. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Sep. 2025 )(Q: Mar. 2026 )
=2811.508/( ( (17375.921 - 6084.777) + (18431.886 - 8459.844) )/ 2 )
=2811.508/( ( 11291.144 + 9972.042 )/ 2 )
=2811.508/10631.593
=26.44 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 26.44% mean?
Egyptian International Pharmaceutical Investments (CAI:PHAR) has a ROCE % of 26.44% as of Mar. 2026.
Is Egyptian International Pharmaceutical Investments' ROCE % too high?
Egyptian International Pharmaceutical Investments' current ROCE % is 26.44%. The Drug Manufacturers industry median ROCE % is 7.01. Egyptian International Pharmaceutical Investments' value of 26.44% is 277.2% above this industry median. Overall, Egyptian International Pharmaceutical Investments has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Egyptian International Pharmaceutical Investments' ROCE % compare to ZTS and UTHR?
Egyptian International Pharmaceutical Investments' ROCE % of 26.44% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.01. Egyptian International Pharmaceutical Investments' value of 26.44% is 277.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.01, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Egyptian International Pharmaceutical Investments's current ROCE % of 26.44% is 277.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Egyptian International Pharmaceutical Investments's current ROCE % is 26.44%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Egyptian International Pharmaceutical Investments stock overvalued right now?
Based on GuruFocus' analysis, Egyptian International Pharmaceutical Investments (CAI:PHAR) is currently considered Significantly Overvalued. The stock's GF Value™ is E£59.67, compared to a current price of E£85.22 — trading 42.8% above its estimated fair value. The current ROCE % is 26.44% and 277.2% above the Drug Manufacturers industry median of 7.01. Egyptian International Pharmaceutical Investments' overall GF Score™ is 69/100 with 12 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Egyptian International Pharmaceutical Investments (CAI:PHAR), the current ROCE % is 26.44% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Egyptian International Pharmaceutical Investments (CAI:PHAR) Overvalued in 2026?

Based on GuruFocus' analysis, Egyptian International Pharmaceutical Investments stock appears to be overvalued. The current stock price of E£85.22 is trading 42.8% above its estimated GF Value™ of E£59.67. GuruFocus considers Egyptian International Pharmaceutical Investments to be Significantly Overvalued.

Key valuation signals for CAI:PHAR:

  • ROCE %: 26.44%
  • GF Value™: E£59.67 vs. price of E£85.22 (42.8% above fair value)
  • GF Score™: 69/100 with 12 warning signs
  • Industry Position: 277.2% above the Drug Manufacturers median

No single metric tells the full story. See the CAI:PHAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Egyptian International Pharmaceutical Investments Business Description

Address 1st Industrial Zone B1, EIPICO, Tenth of Ramadan City, EGY
Egyptian International Pharmaceutical Investments is an Egypt based company pharmaceutical generic drugs. It holds license agreements with a group of pharmaceutical companies to produce their products locally and replace the imported ones. The company produces dosage forms, Spansule capsules, Antibiotics, Lyophilized Products. It exports its products to African, Asian and East European and Latin American Countries.
69GF Score

Get the complete analysis for CAI:PHAR

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

E£85.22
Price
E£59.67
GF Value